Apr 9 |
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
|
Apr 8 |
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
|
Apr 8 |
Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?
|
Apr 2 |
Annovis Bio GAAP EPS of -$6.23 misses by $3.15
|
Apr 2 |
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Apr 1 |
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
|
Mar 21 |
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet
|
Mar 20 |
Annovis to release efficacy data on Alzheimer's drug in April
|
Mar 20 |
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
|
Mar 18 |
Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?
|